{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Duration of response is measured from the first date that criteria are met for complete response or partial response until the first date that criteria for relapse or progressive disease are met.","groups":[{"description":"Dasatinib will be administered continuously at an oral dose of 70 mg BID on Days 1-28 of each 28 day cycle.\n\nIn patients with stable disease after 8 weeks on therapy the dasatinib will be increased to 100 mg BID on Days 1-28 on each 28 day cycle.","id":"OG000","title":"Dasatinib"}],"paramType":"NUMBER","populationDescription":"Only one patient achieved a partial response.","reportingStatus":"POSTED","timeFrame":"Completion of treatment (median duration of therapy was 51 days)","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"cycles"}